Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision		 Previous revision
potassium [2025/01/28 06:38] – adminpotassium [2025/01/28 06:39] (current) – admin
Line 14: Line 14:
  
 **4.Primary Sample:** **4.Primary Sample:**
-Plasma or serum +Plasma or serum [[sample_collection_manual|]]
  
 **5.Patient Preparation:** **5.Patient Preparation:**
Line 68: Line 68:
  
 **20.Turn around time (TAT)** **20.Turn around time (TAT)**
-  6.0 hours after collection, in case of emergency 2.0 hours.+6.0 hours after collection, in case of emergency 2.0 hours.
  
 **21.Critical Value:** **21.Critical Value:**
Line 99: Line 99:
   - Young D.S., Effects of Drugs on Clinical Laboratory Tests, AACc Press Washington, D.C., 1990.   - Young D.S., Effects of Drugs on Clinical Laboratory Tests, AACc Press Washington, D.C., 1990.
   - Document EP3-T:”Guidelines for Manufacturers for Estabilishing Performance Claims for Clinical Chemical Methods, Replication Experiment Evaluation”, National Committee for Clinical Laboratory Standards, Villanova, Pa, 1982.   - Document EP3-T:”Guidelines for Manufacturers for Estabilishing Performance Claims for Clinical Chemical Methods, Replication Experiment Evaluation”, National Committee for Clinical Laboratory Standards, Villanova, Pa, 1982.
-  -  9. Roche Ise Indirect Na K Cl05883962001c501V13.0 +  - Roche Ise Indirect Na K Cl05883962001c501V13.0 
-  -  10. NABL 112 effective from 01/06/2019+  - NABL 112 effective from 01/06/2019
  
 |**Printed copy of this document is considered uncontrolled.** It should be compared with controlled electronic copy before use| |**Printed copy of this document is considered uncontrolled.** It should be compared with controlled electronic copy before use|